Stocktoria
bioAffinity Technologies, Inc. BIAF
Nasdaq · stock · Services-Commercial Physical & Biological Research · website · IPO 2022-08-26
bioAffinity Technologies, Inc. financials (annual)
Bars are annual figures from 2021 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $6.2M | $9.4M | $7.9M | $6.9M | — |
| Gross profit | — | — | — | $4,336 | — |
| R&D expense | $1.4M | $1.5M | $1.5M | $1.4M | $1.0M |
| SG&A expense | $9.9M | $9.9M | $6.8M | $2.5M | $1.1M |
| Operating income | -$10.6M | -$9.0M | -$8.0M | -$4.0M | -$2.2M |
| Interest expense | — | — | $37,125 | $2.5M | $1.0M |
| Income tax | $44,042 | $11,650 | $20,993 | $2,459 | $1,950 |
| Net income | -$14.9M | -$9.0M | -$7.9M | -$8.2M | -$6.3M |
| EPS (diluted) | $-8.66 | $-22.50 | $-0.91 | $-1.81 | — |
| Operating cash flow | -$9.3M | -$7.3M | -$6.0M | -$4.1M | -$2.0M |
| Free cash flow | -$9.4M | -$7.3M | -$6.1M | -$4.3M | — |
| Cash & equivalents | $6.4M | $1.1M | $2.8M | $11.4M | $1.4M |
| Inventory | $53,548 | $27,608 | $18,484 | $5,540 | — |
| Total assets | $11.0M | $6.5M | $8.2M | $12.2M | $1.5M |
| Total liabilities | $3.7M | $3.9M | $3.4M | $1.1M | $13.2M |
| Shareholders' equity | $7.3M | $2.6M | $4.9M | $11.0M | -$15.8M |
Growth · year-over-year · Revenue CAGR -3.7%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue growth | -34.2% | +18.5% | +14.5% | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.